JP2022551691A5 - - Google Patents

Info

Publication number
JP2022551691A5
JP2022551691A5 JP2022521353A JP2022521353A JP2022551691A5 JP 2022551691 A5 JP2022551691 A5 JP 2022551691A5 JP 2022521353 A JP2022521353 A JP 2022521353A JP 2022521353 A JP2022521353 A JP 2022521353A JP 2022551691 A5 JP2022551691 A5 JP 2022551691A5
Authority
JP
Japan
Application number
JP2022521353A
Other languages
Japanese (ja)
Other versions
JP2022551691A (ja
JPWO2021070054A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059377 external-priority patent/WO2021070054A1/en
Publication of JP2022551691A publication Critical patent/JP2022551691A/ja
Publication of JPWO2021070054A5 publication Critical patent/JPWO2021070054A5/ja
Publication of JP2022551691A5 publication Critical patent/JP2022551691A5/ja
Ceased legal-status Critical Current

Links

JP2022521353A 2019-10-08 2020-10-06 ヒト免疫不全ウイルスの複製阻害剤 Ceased JP2022551691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912215P 2019-10-08 2019-10-08
US62/912,215 2019-10-08
PCT/IB2020/059377 WO2021070054A1 (en) 2019-10-08 2020-10-06 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022551691A JP2022551691A (ja) 2022-12-13
JPWO2021070054A5 JPWO2021070054A5 (https=) 2023-10-17
JP2022551691A5 true JP2022551691A5 (https=) 2023-10-17

Family

ID=72896013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521353A Ceased JP2022551691A (ja) 2019-10-08 2020-10-06 ヒト免疫不全ウイルスの複製阻害剤

Country Status (5)

Country Link
US (1) US20220370451A1 (https=)
EP (1) EP4041729B1 (https=)
JP (1) JP2022551691A (https=)
ES (1) ES2962774T3 (https=)
WO (1) WO2021070054A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
US12594276B2 (en) 2024-02-05 2026-04-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
CA2896244C (en) 2013-01-09 2017-07-04 Gilead Sciences, Inc. 5-membered heteroaryls and their use as antiviral agents
CA2897268C (en) 2013-01-09 2018-12-04 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
CN107151223B (zh) 2016-03-10 2020-03-31 中国医学科学院药物研究所 一类n-烷基吲哚类化合物在制备抗流感病毒药物中的用途
KR20230011471A (ko) 2016-08-19 2023-01-20 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
US10836746B2 (en) 2018-02-15 2020-11-17 Gilead Sciences, Inc. Therapeutic compounds
WO2019161280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
WO2020053811A1 (en) * 2018-09-14 2020-03-19 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210395262A1 (en) * 2018-10-24 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
MX2021004593A (es) * 2018-10-24 2021-06-15 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
US20210393633A1 (en) * 2018-10-25 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20210379071A1 (en) * 2018-11-05 2021-12-09 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US20220389007A1 (en) * 2019-10-01 2022-12-08 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂

Similar Documents

Publication Publication Date Title
JP2022551691A5 (https=)
JP1702554S (https=)
BR202020021825U2 (https=)
CN305746572S (https=)
CN305532989S (https=)
CN305536104S (https=)
CN305535849S (https=)
CN305534785S (https=)
CN305534574S (https=)
CN305533228S (https=)
CN305625028S (https=)
CN305740597S (https=)
CN305531460S (https=)
CN305530252S (https=)
CN305528562S (https=)
CN305528210S (https=)
CN305624955S (https=)
CN305527701S (https=)
CN305609507S (https=)
CN305608553S (https=)
CN306386904S (https=)
CN305800686S (https=)
CN305647066S (https=)
CN305597505S (https=)
CN305797065S (https=)